Liver cancer

BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

Retrieved on: 
Tuesday, April 9, 2024
HCC, Malignancy, Disease, Lung, Patient, Bystander effect, Standard of care, Death, Spacecraft, IND, Investigational New Drug, Cancer, Drug resistance, Liver cancer, Therapy, ADC, Hepatocellular carcinoma, FDA, GPC3, Food, CDH3

SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027.

Key Points: 
  • SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027.
  • BC2027, which is BioCity's second first-in-class antibody drug conjugate (ADC) approved for clinical development, targets Glypican 3 (GPC3), a proteoglycan found in the outer membrane of cancer cells.
  • BC2027 binds with very high affinity to GPC3 and efficiently internalizes into cancer cells where it releases its cancer killing payload.
  • Dr. Yong Jiang Hei, CEO of BioCity, noted that "Drug resistance has increasingly become a challenge in cancer treatment.

Blue Faery Awards Liver Cancer Research Grant

Retrieved on: 
Monday, April 8, 2024
HCC, Research, Fairy, Internal medicine, Liver cancer, AstraZeneca, Professor, Caregiver, Patient, Education, Hepatocellular carcinoma, Heidelberg University, Culture, Teaching hospital, University of Marburg, Neoplasm, Cancer, LOS, Gastrointestinal disease, Multimedia, BFA

LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research. Primary liver cancer, also known as Hepatocellular Carcinoma (HCC), is the third leading cause of cancer deaths worldwide. Blue Faery created the award to recognize medical professionals who do innovative HCC research.

Key Points: 
  • Dr. Peter Galle, Professor and Chairman at University Medical Center Mainz, wins a $25K grant
    LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research.
  • Blue Faery's mission is to prevent, treat, and cure primary liver cancer through research, education, and advocacy.
  • Blue Faery provides free comprehensive patient education with its Patient Resource Guides for Liver Cancer .
  • Blue Faery has three public education and awareness programs: Love Your Liver, The Truth About Liver Cancer, and You and Liver Cancer.

TeleDaaS™ Launches Y90 Treatment Planning Service and Announces Pilot Program for Early Adopters

Retrieved on: 
Monday, March 25, 2024
LTD, Y90, Patient, PLLC, Hospital, Research, Cancer, Telehealth, Radiopharmaceutical, Life expectancy, CPT, Liver cancer, ISO, Physician, Health

TeleDaaS is launching a pilot program and enrolling early adopters.

Key Points: 
  • TeleDaaS is launching a pilot program and enrolling early adopters.
  • By eliminating inefficient workflows, TeleDaaS saves time for physicians and helps hospitals improve their revenue capture under existing CPT codes.
  • "With this new service, we are elevating healthcare by providing dosimetry services directly to hospitals,” said TeleDaaS Chief Medical Officer Dr. Mark Crockett, M.D.
  • TeleDaaS is designed to provide highly-scalable, best-in-class dosimetry services that integrate with existing imaging workflows, to transform cancer treatment research and development and treatment planning.

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 19, 2024
Research, OS, NCI, Mutation, EP4, Gene expression, Immunotherapy, RECIST, Patient, National Cancer Institute, Pembrolizumab, Society, AACR, Bevacizumab, Therapy, Nivolumab, ASCO, EP2, SITC, PFS, Liver cancer, FDA, Pharmaceutical industry

“2023 was a transformative year for Tempest.

Key Points: 
  • “2023 was a transformative year for Tempest.
  • We announced strong positive randomized data showing the benefit of TPST-1120 combination therapy compared to standard-of-care in first-line liver cancer,” said Stephen Brady, president and chief executive officer of Tempest.
  • Tempest ended the year with $39.2 million in cash and cash equivalents, compared to $31.2 million on December 31, 2022.
  • Based on current cash and operating plan, Tempest expected to have sufficient resources to fund operations into the second quarter of 2025.

FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population

Retrieved on: 
Thursday, March 14, 2024
Organization, Obesity, Cirrhosis, Exercise, Cardiology, Partnership, F2, Risk, Patient, Fatty liver disease, Hope, Diet, NASH, Language, Liver disease, Liver cancer, Hypertension, FDA, Drug development, JD, Food, GLI

Developed by Madrigal Pharmaceuticals, Rezdiffra™ (resmetirom) was approved for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis, in conjunction with diet and exercise.

Key Points: 
  • Developed by Madrigal Pharmaceuticals, Rezdiffra™ (resmetirom) was approved for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis, in conjunction with diet and exercise.
  • This breakthrough follows years of NASH patient-led, multi-stakeholder advocacy and partnership with researchers in both drug and diagnostic development.
  • “Today’s announcement represents the culmination of the work of the united NASH community.
  • It is particularly satisfying that we can mark Women’s History Month with a breakthrough from a female-founded company.

Can-Fite Reports 2023 Financial Results and Clinical Update

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Human, Psoriasis, Exercise, ALT, Patent, BID, CANF, Patient, CEE, Journal, Policy, EMA, Security (finance), Inflammation, Cancer, Bank statement, European Medicines Agency, Pancreatic cancer, Annual report, Skin, The Annual Report, PASI, Safety, NASH, Use, Liver cancer, FDA, Food, DSM-IV codes, Pharmaceutical industry

(NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended December 31, 2023.

Key Points: 
  • (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended December 31, 2023.
  • EADV is a top ranked peer reviewed journal (impact factor 9.2) that publishes articles on clinical and basic science topics in dermatology.
  • Financial income (expense), net for the year ended December 31, 2023 aggregated $0.56 million compared to financial expense, net of $(0.07) for the year ended December 31, 2022.
  • The Company's consolidated financial results for the year ended December 31, 2023 are presented in accordance with US GAAP Reporting Standards.

Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS® T-cell Therapy

Retrieved on: 
Monday, March 18, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, HCC, Canadian Aviation Regulations, Patient, GPC3, City, Cancer, Glypican 3, ARTEMIS, Clinical trial, Therapy, Safety, Liver cancer, Pharmaceutical industry

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the advancement of its ARYA-3 clinical trial to Phase II ( NCT04864054 ).

Key Points: 
  • Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the advancement of its ARYA-3 clinical trial to Phase II ( NCT04864054 ).
  • The ARYA-3 trial is evaluating Eureka’s investigational ARTEMIS® ECT204 T-cell therapy in adult patients with GPC3-positive advanced hepatocellular carcinoma (HCC), the predominant type of liver cancer.
  • The ARYA-3 trial has successfully completed Phase I and is now enrolling patients in Phase II.
  • Moving to Phase II marks a significant milestone in our mission to advance cutting-edge therapies for cancer treatment,” said Dr. Cheng Liu, President and CEO of Eureka Therapeutics.

Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant

Retrieved on: 
Monday, March 18, 2024
Infectious Diseases, Hospitals, Public Policy, Government, Philanthropy, Managed Care, Health, State, Local, General Health, Foundation, Pregnancy, Liver failure, HBI, Organization, University, Hepatitis B, Disease, CDA, Cirrhosis, Patient, Public, HBV, Woman, Viral hepatitis, Medicaid, Liver cancer, Refugee, HCV, Pharmaceutical industry

“CDA Foundation is very proud to have been selected to distribute these grants,” commented Homie Razavi, the Managing Director of CDA Foundation.

Key Points: 
  • “CDA Foundation is very proud to have been selected to distribute these grants,” commented Homie Razavi, the Managing Director of CDA Foundation.
  • “Loss of diagnosed but untreated patients is a major barrier for countries trying to achieve the viral hepatitis elimination targets.
  • The submission window for the second round of proposals opened in February 2024 for programs with a duration of no more than 18 months.
  • For more information, please visit https://cdafound.org/relink or contact CDA Foundation at [email protected] .

Deepcell Delivers Final Beta Testing Instruments Ahead of Full REM-I Platform Launch

Retrieved on: 
Wednesday, March 13, 2024
Software, Research, Pharmaceutical, Oncology, Technology, Medical Devices, Infectious Diseases, Genetics, Artificial Intelligence, Science, Biotechnology, Stem Cells, Health, Gene, Flow cytometry, Gene expression, Intelligence, Cell biology, Allergy, Newcastle University, Developmental biology, Doctor of Philosophy, Genotype, EMBL, Axon, Eosinophil, Cognition, Neutrophil, Liver cancer, Machine learning, European, Bone marrow, Microscope

Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the launch of its Beta Program for the REM-I platform .

Key Points: 
  • Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the launch of its Beta Program for the REM-I platform .
  • The participants will use the technology to study plasma disorders, blood cancers, immunological functions, genetic perturbations, and other cellular processes.
  • The REM-I platform is a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, an AI Foundation Model, and Axon data suite.
  • “Deepcell's method of integrating artificial intelligence and single cell analysis remains unique in the industry,” said Maddison Masaeli, Ph.D., co-founder and chief executive officer at Deepcell.

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Retrieved on: 
Monday, March 11, 2024
Oncology, Health, FDA, Diabetes, Clinical Trials, Pharmaceutical, Biotechnology, Conference, CKD, CANF, Business development, Inflammation, Pancreatic cancer, Drug development, Liver cancer, CMS, Pharmaceutical industry

Can-Fite’s pipeline of indications includes Namodenoson for the treatment of advanced liver cancer and pancreatic cancer; both indications have been licensed to the Swiss company Ewopharma for Eastern Europe.

Key Points: 
  • Can-Fite’s pipeline of indications includes Namodenoson for the treatment of advanced liver cancer and pancreatic cancer; both indications have been licensed to the Swiss company Ewopharma for Eastern Europe.
  • The liver cancer indication has been licensed as well to CMS in China and CKD in South Korea.
  • Piclidenoson has been out-licensed to Cipher in Canada; Gebro Pharma for Swiss, Spain, Austria; CMS for China; and Kyongboo for South Korea.
  • “Advanced liver cancer and pancreatic cancer are Can-Fite’s clinical-stage indications for Namodenoson and am delighted with the interest that Namodenoson is raising with companies that will participate in the Bio Europe Conference and are experts in drug development and distribution in the oncology arena.